Sage Private Wealth Group LLC Increases Stock Position in Johnson & Johnson $JNJ

Sage Private Wealth Group LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.0% during the second quarter, HoldingsChannel.com reports. The fund owned 3,304 shares of the company’s stock after purchasing an additional 381 shares during the quarter. Sage Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $505,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ellis Investment Partners LLC grew its position in Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after buying an additional 62 shares during the last quarter. Cypress Wealth Services LLC grew its position in Johnson & Johnson by 0.9% in the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after buying an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN grew its position in Johnson & Johnson by 11.2% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after buying an additional 64 shares during the last quarter. Global Strategic Investment Solutions LLC grew its position in Johnson & Johnson by 3.5% in the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after buying an additional 65 shares during the last quarter. Finally, JSF Financial LLC lifted its holdings in Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock valued at $457,000 after acquiring an additional 65 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Citigroup raised their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday. HSBC raised their target price on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.59.

Johnson & Johnson Trading Up 0.6%

NYSE:JNJ opened at $193.27 on Friday. The company has a market capitalization of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40. The stock has a fifty day simple moving average of $180.49 and a 200-day simple moving average of $164.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.